EGFR and non-small cell lung carcinoma: Several randomised trials of first-line treatment have confirmed superiority of TKIs gefitinib, erlotinib or afatinib over platinum-based doublets1–3 and led to registration of these drugs for first-line treatment of metastatic EGFR-mutated NSCLC.